New copycat cancer drug tested against original
Disease control
Terminated
This study tested a new, potentially lower-cost version (biosimilar) of an existing melanoma drug called nivolumab (Opdivo). It compared how the body processes the drugs, their effectiveness, and safety when combined with another drug (ipilimumab/Yervoy) in adults with advanced s…
Phase: PHASE3 • Sponsor: Sandoz • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC